sartorius annual report 2019

 

At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe. For this reason, please refer to a detailed description of the opportunities and risks as well as the risk management system for the Sartorius Group on pages 57 et seq. Equity rose from 973.4 million euros to 1,081.2 million euros at year-end. 2019: SARTORIUS STEDIM BIOTECH SA: Information on Document Availability: EQ. Annual … The planned acquisition of parts of Danaher's life science portfolio announced in October 2019 covers, among others, the FortéBio business for label-free biomolecular characterization, as well as chromatography hardware and resins, with which Sartorius would extend its portfolio in the downstream area. This is a translation of the original German-language press release. Made In NYC | The planned acquisition of parts of Danaher's life science portfolio announced in October 2019 covers, among others, the FortéBio business for label-free biomolecular characterization, as well as chromatography hardware and resins, with which Sartorius would extend its portfolio in the downstream area. Download 4238 Kb. ... SARTORIUS STEDIM BIOTECH SA: Annual report of the liquidity contract with the s.. EQ. This equates to an 11% increase or around 900 people more than a year ago. Key performance indicators for fiscal 2019, In millions of €, unless otherwise specified, 1) In constant currencies, abbreviated as "cc" 2) Acc. Global Cell Culture Market Report 2020-2030 Featuring Thermo Fisher Scientific, Corning, Becton, Dickinson and Co, Eppendorf, Merck KGAA, Lonza, Sartorius, Promocell, Danaher and Sartorius ", Overproportionate profit growth; increase in dividends planned. and 65 et seq. "Over the past years, we have evolved from a product supplier for various sectors into an application-oriented solutions provider for life science research and the biopharmaceutical industry. In line with its strong growth, Sartorius further increased its number of employees. Find new perspectives, new products and all important figures in our 2020 annual report. Download 2219 Kb. In particular, the company's customer-facing units, research and development, and production reported staff gains. For the full year of 2019, Sartorius expects to continue to grow profitably. Beyond operating business development and the integration of acquisitions, additional topics are on the 2020 agenda at Sartorius. Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn. Sartorius shall not assume any liability for the correctness of this translation. Annual 27.3 MB We will provide a hard copy of our annual report containing our audited consolidated financial statements, free of charge, to our stakeholders … The Lab Products & Services Division should increase its sales revenue by 7% to 10%, with Biological Industries projected to contribute around 2.5 percentage points to growth. 3 Further information is provided on page 28 of the Sartorius 2019 Annual Report This press release contains forward-looking statements about the future development of the Sartorius Group. 2017 Corporate Responsibility Report May 22, 2018. In connection with IFRS 162), the equity ratio decreased slightly from 38.5% as of December 31, 2018, to 38.0%. The Sartorius Group continued to make substantial investments in expanding its global capacity, even though, as expected, its CAPEX ratio1) decreased upon the completion of several large projects to 12.3% (2018: 15.2%). Mit einem Umsatzplus von 14,8 % auf etwas mehr als 1,8 Milliarden Euro bei einer um 1,2 Prozentpunkte auf 27,1 % … The dividend payout ratio of 23.0% would be approximately at the level of the previous years (2018: 24.0%). The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. Wie Sie ukrainische Single Frauen kennenlernen, die Kinder haben. It showed robust performance in a partly challenging economic environment, achieving sales growth of 5.9% (reported: +7.5%) to 454.9 million euros. The division's respective margin rose due to economies of scale and as a consequence of the change in IFRS 162), from 28.6% to 29.6%. +49 210 244 00 24. info@sartorius-werkzeuge.de. Registration Document 2018 Interactive link Apr 12, 2019. To the website. 2018. Underlying EBITDA1) rose overproportionately again relative to sales, as in the prior year, by 22.4% to 495.8 million euros in 2019; the respective margin was 27.1% (previous year: 25.9%) in line with our guidance. This equates to an 11% increase or around 900 people more than a year ago. The Americas region achieved a 17.4% increase in sales to 629.9 million euros, contributing around 35% to Group revenue. At year-end 2019, the Group employed 9,016 staff members. The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry, listed on the German MDAX and TecDAX stock markets. From a technological standpoint as well, we have taken important steps to further increase the relevance of our product portfolio for customers. Sartorius, a leading international partner of biopharmaceutical research and the industry, confirmed its preliminary figures with the publication of its 2018 Annual Report. At year-end 2019, the Group employed 9,016 staff members. 3.070. In December 2019, Sartorius had acquired a majority stake in Biological Industries, an Israeli company specializing particularly in the development and manufacture of cell culture media for cell and gene therapies. "Over the past years, we have evolved from a product supplier for various sectors into an application-oriented solutions provider for life science research and the biopharmaceutical industry. März 2019 vorschlagen, die Dividende zum neunten Mal in Folge zu erhöhen und 0,62 Euro je Vorzugsaktie bzw. At year-end 2019, the Group employed 9,016 staff members. Sartorius, a leading international partner of life science research and the biopharmaceutical industry, confirmed its preliminary figures upon publication of its 2019 Annual Report today. Investor News . Sartorius projects that it will increase Group sales in fiscal 2020 by 10% to 13%, with the acquisition of Biological Industries, completed at the end of 2019, expected to contribute approx. Growth was almost entirely organic as the acquisition of the cell culture media specialist Biological Industries completed in December 2019 contributed only marginally to this increase. Sartorius dynamically increased its sales in all regions compared with the previous year. Annual Report 2019 PDF; Audio replay of the analyst conference call on April 29, 2020 Audio replay (PIN 868607) Financial Statements 2019 of Epigenomics AG (German–HGB) PDF; 9-Month Report 2019 PDF; 6-Month Report 2019 PDF; 3-Month Report 2019 PDF . The above forecast does not consider the acquisition of parts of Danaher's life science portfolio, which was announced on October 21, 2019, and is currently undergoing antitrust clearance. All forecasts are based on constant currencies, as in the past years. Group sales revenue rose in constant currencies by 14.8% (reported: +16.7%) to 1,827.0 million euros. We want to underscore this transformation and communicate it even more strongly than in the past with our new brand claim of 'Simplifying Progress' and our new brand look," said Dr. Joachim Kreuzburg. This is a translation of the original German-language press release. Der Wachstumskurs unseres Konzerns spieg. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. : 1 Founded in 1870, the Göttingen-based company currently employs over 9,000 persons. At the end of 2019, more than 9,000 people were employed at the Group's … Our official page for the 2020 annual report looks back at the past year and outlines the Group’s prospects for the future. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. We aim to raise our revenue by 10% to 13% and further increase our profitability in 2020.". Contact: Petra Kirchhoff Head of Corporate Communications and Investor Relations +49-(0)551-308-1686[email protected], Cision Distribution 888-776-0942 Report of the Executive Board. 3 Further information is provided on page 28 of the Sartorius 2019 Annual Report This press release contains forward-looking statements about the future development of the Sartorius Group. In December 2019, Sartorius had acquired a majority stake in Biological Industries, an Israeli company specializing particularly in the development and manufacture of cell culture media for cell and gene therapies. These are determined with the aim of improving the comparability of business performance over time and within the industry. A hard copy of the audited consolidated financial statements can also be requested free of charge by sending an email to investor@sap.com or via phone +49 6227 7-67336. Commerce Policy | Sartorius projects that it will increase Group sales in fiscal 2020 by 10% to 13%, with the acquisition of Biological Industries, completed at the end of 2019, expected to contribute approx. Document de Référence. Sartorius, a leading international partner of life science research and the biopharmaceutical industry, confirmed its preliminary figures upon publication of its 2019 Annual Report today. Harkortstraße 54. Preference shares closed the year 2020 at, €343.60 up around 80% from year-end 2019. ), Bioprocess Solutions strong; Lab Products & Services robust. Disclaimer | Q4 2020 Sartorius AG Annual Report. Compared to headcount as of December 31, 2019, this number rose by 756. Sartorius Group 2019 Annual Report 9. Further, this has resulted in reporting longer-term lease payments as depreciation and, accordingly, in a somewhat higher EBITDA, but does not entail any material changes concerning the Group's relevant net profit or earnings per share. HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American, https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations/news-financial-publications, https://www.sartorius.com/en/company/newsroom/downloads-publications. "The once again very positive development of the Group shows that we have laid a strong foundation for sustained profitable growth by concentrating in both divisions on the dynamic biopharma sector," commented CEO Dr. Joachim Kreuzburg on the past fiscal year. to the customer's location 3) Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items 4) Relevant net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects, 2019 Annual Report https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations/news-financial-publications, March 26, 2020: Annual Shareholders' MeetingApril 21, 2020: Publication of first-quarter figures (January to March 2020), Current image files https://www.sartorius.com/en/company/newsroom/downloads-publications. 1.5 percentage points to this growth. auch in den Kursen der Sartorius-Aktien wider. of the 2019 Annual Report. 2021-02-21 23:50 Sartorius Group 2019 Annual Report 9 . - Group sales revenue up 14.8%; order intake up 14.8%; underlying EBITDA margin 27.1%, - Dividend proposal: 0.71 euros per preference share; 0.70 euros per ordinary share, - Positive outlook for 2020: Sales growth of 10% to 13% with a further increase in earnings margin projected. ), Bioprocess Solutions strong; Lab Products & Services robust. In addition, Sartorius will be celebrating its 150-year company anniversary. Sartorius dynamically increased its sales in all regions compared with the previous year. Wie Sie ukrainische Single Frauen kennenlernen, die Kinder haben. The ratio of capital expenditures (CAPEX) to sales revenue1) is expected to be around 10% (2018: 12.3%). In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. nnal Report 2019 The Afnic General Assembly and annual dinner were the occasion for its members and teams to thank Emmanuel Sartorius for his efforts at the head of our association these past six years and to welcome Godefroy Beauvallet, our new Chair. When typing in this field, a list of search results will appear and be automatically updated as you type. Rapport RSE. Annual Report 2018 –2019 n e w y o R k 2 0 1 9. 1.5 percentage points to this growth. 3 Further information is provided on page 28 of the Sartorius 2019 Annual Report This press release contains forward-looking statements about the future development of the Sartorius Group. Press releases . Sartorius shall not assume any liability for the correctness of this translation. 2018: € 1,827.0m. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe. Slides- Webcasts Financial Reports. Sales revenues. The division's order intake1) rose significantly as well by 18.0% (reported: +19.9%) to 1,479.3 million euros. As a result, the Group now owns production facilities for cell culture media. 2019: SARTORIUS STEDIM BIOTECH SA: HALF-YEAR report of the liquidity contract with th.. EQ. ... 2019. Relevant net profit1) rose by 19.2% from 175.6 million euros a year ago to 209.3 million euros, yielding earnings per ordinary share of 3.06 euros (2018: 2.56 euros) and earnings per preference share of 3.07 euros (2018: 2.57 euros). With sales revenue surging 14.8% to just over €1.8 billion and the EBITDA margin up 1.2 percentage points at … If you wish to get hold of older issues of our publications, please go to our archive. 0,61 Euro je Stammaktie auszuschütten. Sartorius Stedim Filters's annual revenues are $10-$50 million (see exact revenue data) and has 100-500 employees. Sartorius therefore continues to have a very sound balance sheet and financial base. Sartorius hat seine sehr dynamische Entwicklung auch 2019 fortgesetzt und das Jahr mit zweistelligen Wachstumsraten bei Umsatz und Ertrag abgeschlossen. EMEA (Europe, Middle East and Africa) increased its revenue by 11.2% to 733.4 million euros, accounting for 40% of the Group's consolidated sales. Sartorius annual revenue increased from €1.8 billion in 2019 to €2.3 billion in 2020, a (27.8%) increase. SARTORIUS Werkzeuge GmbH & Co. KG. As a result, the Group now owns production facilities for cell culture media. The corresponding margin was positively affected by IFRS 162) and stood at 19.6%, up from the previous year's level of 18.5%. Regarding profitability, Sartorius forecasts that its underlying EBITDA margin1) will increase year over year from 27.1% to about 27.5%. Sartorius confirmed its preliminary figures upon publication of its 2019 Annual Report. The Lab Products & Services Division specializes in technologies and products for laboratories in the pharma sector and in life science research as well as in a few additional segments. At a glance. If you wish to get hold of older issues of our publications, please go to our archive. In line with its strong growth, Sartorius further increased its number of employees. It showed robust performance in a partly challenging economic environment, achieving sales growth of 5.9% (reported: +7.5%) to 454.9 million euros. Report of the Executive Board; Executive Board; Report of the Supervisory Board; Sartorius Shares; Combined Group Management Report; Consolidated Financial Statements and Notes; Supplementary Information; Annual report 2019. Sartorius proposes div of 0.71 eur per preference share. 2018. As expected, slightly less than one percentage point of this increase was attributable to the IFRS 162) Standard required to be applied for the first time in 2019. For the Bioprocess Solutions Division, the Executive Board projects sales growth of 11% to 14%, with consolidation of Biological Industries expected to contribute about one percentage point to this gain. This gain was fueled by ongoing strong demand across all product categories, particularly in project business in Asia. The year 2019 consolidated financial statements of Sartorius Stedim Biotech prepared using international accounting standards and the report of the statutory auditors relating to these statements, and the Group 2019 management report appearing on pages 95 to 145 and 17 to 58 Underlying EBITDA1) rose overproportionately again relative to sales, as in the prior year, by 22.4% to 495.8 million euros in 2019; the respective margin was 27.1% (previous year: 25.9%) in line with our guidance. (All growth rates for the regions are in constant currencies. Due to strong net cash flow from operating activities and despite the intensive investment activity and successful acquisition, the company's ratio of net debt to underlying EBITDA1) was 2.0 and thus below the prior-year figure of 2.4.